PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2020-12-28

Date Title Company
28-Dec-2020 Prescription Delivery Service Market Pegged for Robust Expansion During 2020-2030 MARKITWIRED
28-Dec-2020 Elevar Therapeutics Announces Licensing Agreement with Inceptua Group for Commercialization of Apealea® (Paclitaxel Micellar) in Europe Elevar Therapeutics
28-Dec-2020 Elevar Therapeutics Announces Licensing Agreement with Inceptua Group for Commercialization of Apealea® (Paclitaxel Micellar) in Europe Elevar Therapeutics
28-Dec-2020 Elevar Therapeutics Announces Licensing Agreement with Inceptua Group for Commercialization of Apealea® (Paclitaxel Micellar) in Europe Elevar Therapeutics
28-Dec-2020 Elevar Therapeutics Announces Licensing Agreement with Inceptua Group for Commercialization of Apealea® (Paclitaxel Micellar) in Europe Elevar Therapeutics
28-Dec-2020 Burgeoning Demand for Benign Prostatic Hyperplasia Testing to Fuel Market Growth Thorough the COVID-19 Crisis Period MARKITWIRED
28-Dec-2020 Global Ventricular Tachycardia Treatment Market to Register Growth in Incremental Opportunity after COVID-19 pandemic MARKITWIRED
28-Dec-2020 Impact of COVID-19 pandemic on Acute Myeloid Leukemia Therapeutics Market Structure and Its Segmentation MARKITWIRED
28-Dec-2020 Injectable Benzodiazepine Market Size 2020 by Top Key Players, Global Trend, Types, Applications, Regional Demand, Forecast to 2027 MARKITWIRED
28-Dec-2020 Tip Location Devices Market Shows Outlook and Analysis by Manufacturers with Regions also includes Type and Application, Forecast and Industrial Analysis to 2026 MARKITWIRED
28-Dec-2020 Guidewires Market Outlook Highlights Major Opportunities by 2030 MARKITWIRED
28-Dec-2020 Swab and Viral Transport Medium Market To Witness Huge Gains Over 2020-2026 MARKITWIRED
28-Dec-2020 Innovent Announces the NMPA Granted New Indication Approval for BYVASDA® (Bevacizumab Biosimilar) for the Treatment of Adult Recurrent Glioblastoma Innovent Biologics, Inc.
28-Dec-2020 Innovent Announces the NMPA Granted New Indication Approval for BYVASDA® (Bevacizumab Biosimilar) for the Treatment of Adult Recurrent Glioblastoma Innovent Biologics, Inc.
28-Dec-2020 Innovent Announces the NMPA Granted New Indication Approval for BYVASDA® (Bevacizumab Biosimilar) for the Treatment of Adult Recurrent Glioblastoma Innovent Biologics, Inc.
28-Dec-2020 Innovent Announces the NMPA Granted New Indication Approval for BYVASDA® (Bevacizumab Biosimilar) for the Treatment of Adult Recurrent Glioblastoma Innovent Biologics, Inc.